Mumbai, Dec 26 (UNI) Pharma major Lupin said on Sunday that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) Sevelamer Carbonate for Oral Suspension, 0.8 g and 2.4 g packets to market a generic equivalent of Renvela for Oral Suspension, 0.8 g and 2.4 g Packets of Genzyme.
This product will be manufactured at Lupin’s Goa facility.
Sevelamer Carbonate for Oral Suspension had estimated annual sales of USD 51.7 million in the U.S. (IQVIA MAT September 2021).
UNI JS ACL1735